Literature DB >> 16229988

Factor structure and external validity of the PANSS revisited.

Edwin J C G Van den Oord1, Dan Rujescu, Jaime R Robles, Ina Giegling, Claire Birrell, József Bukszár, Lenn Murrelle, Hans-Jürgen Möller, Lefkos Middleton, Pierandrea Muglia.   

Abstract

Considerable controversy exists concerning the positive and negative syndrome scale (PANSS), one of the most widely used instruments in schizophrenia research. In this article we revisited the factor structure and external validity of the PANSS in a sample of 500 participants with DSM IV diagnoses of schizophrenia. We found that a model with six latent factors provided a relatively good fit, considered adequate by two rules of thumb. Five factors corresponded closely to those typically derived in other studies: Negative, Positive, Excited/Activation, Anxious-Depressed/Dysphoric, and Disorganized/Autistic preoccupation. The sixth factor seemed to have face validity and was labeled Withdrawn. With the exception of Anxious-Depressed/Dysphoric, Cronbach's Alpha ranged from 0.70 to 0.85 suggesting an acceptable internal consistency. External validity was studied through correlations with socio-demographic variables, DSM IV (subtype) diagnoses, clinical characteristics, and drug use. The many significant correlations suggested that the six PANSS scales measure meaningful aspects of schizophrenia. Furthermore, the pattern of correlations varied, providing evidence that the scales assessed partly different aspects of the disease. Our analyses also suggested that some of the controversy about the PANSS can possibly be attributed to methodological factors where the substantial cross-loadings of some PANSS items may play an important role.

Entities:  

Mesh:

Year:  2005        PMID: 16229988     DOI: 10.1016/j.schres.2005.09.002

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  54 in total

Review 1.  Avolition and expressive deficits capture negative symptom phenomenology: implications for DSM-5 and schizophrenia research.

Authors:  Julie W Messinger; Fabien Trémeau; Daniel Antonius; Erika Mendelsohn; Vasthie Prudent; Arielle D Stanford; Dolores Malaspina
Journal:  Clin Psychol Rev       Date:  2010-09-18

2.  The lack of impact of quality-of-life measures in schizophrenia: a shared responsibility?

Authors:  Laurent Boyer; Pascal Auquier
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

3.  Sparse factors for the positive and negative syndrome scale: which symptoms and stage of illness?

Authors:  Ariana Anderson; Marsha Wilcox; Adam Savitz; Hearee Chung; Qingqin Li; Giacomo Salvadore; Dai Wang; Isaac Nuamah; Steven P Riese; Robert M Bilder
Journal:  Psychiatry Res       Date:  2015-01-06       Impact factor: 3.222

4.  Intrinsic Connectivity Patterns of Task-Defined Brain Networks Allow Individual Prediction of Cognitive Symptom Dimension of Schizophrenia and Are Linked to Molecular Architecture.

Authors:  Ji Chen; Veronika I Müller; Juergen Dukart; Felix Hoffstaedter; Justin T Baker; Avram J Holmes; Deniz Vatansever; Thomas Nickl-Jockschat; Xiaojin Liu; Birgit Derntl; Lydia Kogler; Renaud Jardri; Oliver Gruber; André Aleman; Iris E Sommer; Simon B Eickhoff; Kaustubh R Patil
Journal:  Biol Psychiatry       Date:  2020-10-03       Impact factor: 13.382

5.  Bifactor Modeling of the Positive and Negative Syndrome Scale: Generalized Psychosis Spans Schizoaffective, Bipolar, and Schizophrenia Diagnoses.

Authors:  Ariana E Anderson; Stephen Marder; Steven P Reise; Adam Savitz; Giacomo Salvadore; Dong Jing Fu; Qingqin Li; Ibrahim Turkoz; Carol Han; Robert M Bilder
Journal:  Schizophr Bull       Date:  2018-10-17       Impact factor: 9.306

6.  No association between NRG1 and ErbB4 genes and psychopathological symptoms of schizophrenia.

Authors:  Sarah Tosato; Martina Zanoni; Chiara Bonetto; Federica Tozzi; Clyde Francks; Elisa Ira; Simona Tomassi; Mariaelena Bertani; Dan Rujescu; Ina Giegling; David St Clair; Michele Tansella; Mirella Ruggeri; Pierandrea Muglia
Journal:  Neuromolecular Med       Date:  2014-08-21       Impact factor: 3.843

7.  Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections.

Authors:  Enrico Domenici; David R Willé; Federica Tozzi; Inga Prokopenko; Sam Miller; Astrid McKeown; Claire Brittain; Dan Rujescu; Ina Giegling; Christoph W Turck; Florian Holsboer; Edward T Bullmore; Lefkos Middleton; Emilio Merlo-Pich; Robert C Alexander; Pierandrea Muglia
Journal:  PLoS One       Date:  2010-02-11       Impact factor: 3.240

8.  Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.

Authors:  J L McClay; D E Adkins; K Aberg; S Stroup; D O Perkins; V I Vladimirov; J A Lieberman; P F Sullivan; E J C G van den Oord
Journal:  Mol Psychiatry       Date:  2009-09-01       Impact factor: 15.992

9.  Multiple independent loci at chromosome 15q25.1 affect smoking quantity: a meta-analysis and comparison with lung cancer and COPD.

Authors:  Nancy L Saccone; Robert C Culverhouse; Tae-Hwi Schwantes-An; Dale S Cannon; Xiangning Chen; Sven Cichon; Ina Giegling; Shizhong Han; Younghun Han; Kaisu Keskitalo-Vuokko; Xiangyang Kong; Maria Teresa Landi; Jennie Z Ma; Susan E Short; Sarah H Stephens; Victoria L Stevens; Lingwei Sun; Yufei Wang; Angela S Wenzlaff; Steven H Aggen; Naomi Breslau; Peter Broderick; Nilanjan Chatterjee; Jingchun Chen; Andrew C Heath; Markku Heliövaara; Nicole R Hoft; David J Hunter; Majken K Jensen; Nicholas G Martin; Grant W Montgomery; Tianhua Niu; Thomas J Payne; Leena Peltonen; Michele L Pergadia; John P Rice; Richard Sherva; Margaret R Spitz; Juzhong Sun; Jen C Wang; Robert B Weiss; William Wheeler; Stephanie H Witt; Bao-Zhu Yang; Neil E Caporaso; Marissa A Ehringer; Tim Eisen; Susan M Gapstur; Joel Gelernter; Richard Houlston; Jaakko Kaprio; Kenneth S Kendler; Peter Kraft; Mark F Leppert; Ming D Li; Pamela A F Madden; Markus M Nöthen; Sreekumar Pillai; Marcella Rietschel; Dan Rujescu; Ann Schwartz; Christopher I Amos; Laura J Bierut
Journal:  PLoS Genet       Date:  2010-08-05       Impact factor: 5.917

10.  A genome-wide investigation of SNPs and CNVs in schizophrenia.

Authors:  Anna C Need; Dongliang Ge; Michael E Weale; Jessica Maia; Sheng Feng; Erin L Heinzen; Kevin V Shianna; Woohyun Yoon; Dalia Kasperaviciūte; Massimo Gennarelli; Warren J Strittmatter; Cristian Bonvicini; Giuseppe Rossi; Karu Jayathilake; Philip A Cola; Joseph P McEvoy; Richard S E Keefe; Elizabeth M C Fisher; Pamela L St Jean; Ina Giegling; Annette M Hartmann; Hans-Jürgen Möller; Andreas Ruppert; Gillian Fraser; Caroline Crombie; Lefkos T Middleton; David St Clair; Allen D Roses; Pierandrea Muglia; Clyde Francks; Dan Rujescu; Herbert Y Meltzer; David B Goldstein
Journal:  PLoS Genet       Date:  2009-02-06       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.